Europe Immunoprecipitation Market Research Report – Segmented By Type, Product, End-User & Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 12703
Pages: 110

Europe Immunoprecipitation Market Size (2023 to 2028)

The size of the immunoprecipitation market in the European region is expected to be growing at a CAGR of 5.42% from 2023 to 202 and value USD 270.27 million by 2028 from USD 207.58 million in 2023.

The incidence of cancer is growing considerably in the European region, which is a key factor driving the immunoprecipitation market in this region. Cancer patients have onconeural antibodies, which are connected to paraneoplastic neurological disorders. Immunoprecipitation is used to identify antigens in a protein mixture response to protein for identification. In a cancer patient, a tumor allows a small portion of cancer cells to survive and regrow, leading to cancer in an advanced stage. In these people, we can know the level of protein-protein interactions (PPIs). For this, we have a co-immunoprecipitation (co-IP) analysis that examines the amount and PPIs of target proteins immunoprecipitated from individual cells and finds the exact location of the specific protein which detects cancer.

YOY increase in the prevalence of autoimmune diseases further promotes the growth of the European immunoprecipitation market. Immunoprecipitation provides instruments for detecting autoantibodies in various diseases, including cancer, neurologic conditions, and even acute illnesses. Antibodies are the main ones to keep our immune system strong to fight infections. These antibodies play an essential role in the diagnosis of many infectious diseases. Furthermore, these antibodies are used to treat these autoimmune diseases, which specific antibodies can identify through IP. Detecting early symptoms in a person is an essential factor for successful treatment, Utilization of clinical biomarkers for many diseases for effective treatment.  

Growing biomarker discovery is favoring the market growth. Autoantibodies, which are self-proteins, are very helpful for diagnosing autoimmune illnesses. In addition, autoantibodies are also present as biomarkers in many other human diseases, such as neurological disorders and degenerative diseases, where the primary pathophysiology is not necessarily connected to autoimmune.

The immunoprecipitation market in this region is further anticipated to be driven by chromatin immunoprecipitation. Technology based on antibodies is used to study DNA-binding proteins and the DNA target. The biomarkers are used to find an individual protein-DNA interaction, several protein-DNA interactions, or interactions across the whole genome or a subset of genes. DNA-protein interactions are essential in gene transcription, replication, and recombination. Immunoprecipitation is also used in the detection of the Covid-19 virus. Luciferase IP system is used to detect the confirm of the virus is present in the body or not. LIPS to see antibody responses to SARS‐CoV‐2 spike and nucleocapsid proteins in COVID‐19 patients.

However, a lack of awareness of these types of procedures, a low number of samples for the research, and a lack of regulatory approvals for the study are hampering the market growth.

This research report on the European immunoprecipitation market has been segmented and sub-segmented into the following categories.

By Product:

  • Kits
  • Reagents
    • Antibodies
    • Beads
    • Others

By Type:

  • Individual protein
  • Protein complex
  • Chromatin
  • Ribonucleoprotein
  • Tagged proteins

By End-User:

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Europe accounted for a considerable share of the global market in 2022, owing to the increased investments in R&D and immunoprecipitation techniques in this region. There are different methods of identifying the protein for biological processes. One of the most used techniques in the United Kingdom is Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins. This is used to identify transcriptional co-factors and chromatin-associated proteins. Increasing the purification of a protein boosts the market forward. The team of scientists in this region found the advanced technique in immunoprecipitants.

Italy is anticipated to grow at a healthy CAGR in the European region during the forecast period. The increasing life science sector in Italy also drives the market forward. The life science sector is increasing gradually in Italy due to an increase in pharmaceutical and biotechnology industries, the manufacturing of biomedical devices, and health services. The life sciences sector includes research to improve knowledge on the relationship between DNA, lifestyle, environment, and diseases. In addition, increasing protein purification methods and growing research and development drive the market forward.


Companies playing a vital role in the European immunoprecipitation market profiled in this report are Merck KGaA, Thermo Fisher Scientific, Abcam, Bio-Rad Laboratories, Abbkine Scientific Co. Ltd., Cell Signaling Technology, Rockland Immunochemicals, BioLegend, Takara Bio, GenScript Biotech Corporation, and Geno Technology.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample